Bipolar Disorder and Schizophrenia in Children & Adolescents: Diagnostic and Treatment Issues

Bipolar Disorder and Schizophrenia in children and adolescents: Diagnostic and Treatment Issues

For venue information, please click on the venue name below. September 20, 2008 • 8:00 am – 12:15 pm Zeum Museum • 221 4th Street at Howard • San Francisco, CA October 11, 2008 • 8:00 am – 12:15 pm Boston Children’s Museum • 300 Congress Street • Boston, MA January 24, 2009 • 8:00 am – 12:15 pm Miami Museum of Science • 3280 S. Miami Avenue • Miami, FL This activity is supported by an unrestricted educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.
Faculty
Chair: Karen D. Wagner, MD, PhD Director, Division of Child and Adolescent Psychiatry Department of Psychiatry and Behavioral Sciences University of Texas Medical Branch Galveston, TX Distinguished Faculty: Christoph U. Correll, MD Medical Director, Recognition and Prevention Program Zucker Hillside Hospital Assistant Professor of Psychiatry and Behavioral Sciences Albert Einstein School of Medicine Glen Oaks, NY Jean A. Frazier, MD Director, Child and Adolescent Neuropsychiatric Research Program Director, Child Psychopharmacology Co-Director, Center for Child and Adolescent Development Cambridge Health Alliance Associate Professor of Psychiatry Harvard Medical School Boston, MA Robert M.A. Hirschfeld, MD Titus H. Harris Chair Harry K. Davis Professor Department of Psychiatry and Behavioral Sciences University of Texas Medical Branch Galveston, TX Robert A. Kowatch, MD Director, Pediatric Mood Disorders Center Professor of Psychiatry and Pediatrics Cincinnati Children's Hospital Medical Center Cincinnati, OH Adelaide S. Robb, MD Associate Professor, Psychiatry and Behavioral Sciences and Pediatrics George Washington University School of Medicine and Health Sciences Washington, DC
Statement of Need and Program Overview
Bipolar disorder and other related psychiatric conditions (i.e., schizophrenia) are debilitating illnesses that affect individuals across all ages. Specific diagnostic and treatment challenges exist in children and adolescents with these psychiatric conditions. Diagnostically, these conditions may pose greater treatment challenges as they are often associated with other psychiatric comorbidities, severe disease, and treatment resistance. Considering the potential lifelong disability associated with bipolar disorder and schizophrenia, it is essential to perform a thorough diagnostic evaluation. Treatment of these conditions often involves a multi-modal approach including psychoeducation, family and supportive psychotherapy, and pharmacotherapy (i.e., mood stabilizers, antipsychotics). This series of CME symposia Bipolar Disorder and Schizophrenia in Children & Adolescents: Diagnostic and Treatment Issues, chaired by Karen D. Wagner, MD, PhD (Director, Childhood and Adolescent Psychiatry, University of Texas Medical Branch, Galveston) will discuss advances in diagnostic (i.e., neuroimaging) and clinical issues, as well as review the extant literature and recommendations for pharmacotherapy and its optimal use (including minimizing complications) in these patients. Finally, challenging patient cases will be presented to emphasize key learning objectives and to share the emerging treatment paradigms based on the clinical expertise of leading pediatric and adolescent psychiatrists in the field.
Target Audience
Psychiatrists, psychiatric nurses, psychologists, and other mental healthcare professionals involved in childhood and adolescent psychiatry.
Learning Objectives
After attending this presentation, the attendee should be able to: • Describe the neuropharmacologic basis of bipolar disorder and schizophrenia as related to current and novel drug therapies; • Summarize the multi-modality approach to treating childhood and adolescent bipolar disorder and schizophrenia; • Identify clinical treatment options for childhood and adolescent bipolar disorder taking into account symptom presentation, presence of comorbid diagnosis, drug efficacy, adverse effects, drug-drug interactions, and data from current clinical studies; • Discuss the importance of proper diagnosis and treatment of early-onset schizophrenia-spectrum (EOSS) disorders; • Integrate and summarize existing guidelines in optimizing pharmacotherapy, including monitoring and treating for potential complications.
Accreditation
Continuing Medical Education This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of North Texas Health Science Center at Fort Worth Office of Professional and Continuing Education (PACE) and Letters & Sciences. The University of North Texas Health Science Center at Fort Worth PACE is accredited by the ACCME to provide continuing medical education for physicians. The University of North Texas Health Science Center at Fort Worth PACE is accredited by the American Osteopathic Association to award continuing medical education to physicians. Credit Designation The University of North Texas Health Science Center at Fort Worth PACE designates this educational activity for a maximum of 3.5 AMA PRA Category 1 Credits(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Continuing Nursing Education Letters & Sciences is an approved provider of continuing nursing education by the New Jersey State Nurses Association (NJSNA), Provider Number P205-5/07-10. NJSNA is accredited by the American Nurses Credentialing Center's Commission on Accreditation. Letters & Sciences is an approved provider by the California Board of Registered Nursing. Provider Number: CEP14145. This activity is designated for 3.5 contact hours.
Americans With Disabilities Act
The Letters & Sciences Event Staff will assist those whose attendance may require special services. Call 800-238-9620 PIN # 5216 prior to the event for special accommodations.

We DO NOT sell or distribute any personal information on our system and it will only be shared with program manager(s) for this specific event, at which time all information is then protected by their individual privacy policies. During registration all users are required to give their contact information. This information is used ONLY to contact the users with information related to this specific event. When users submit sensitive information via this site, that information is encrypted and is protected with the best encryption software in the industry–SSL.